12-Week Open-Label Extension Study of TNX-102 SL in PTSD Patients
Status:
Terminated
Trial end date:
2018-07-27
Target enrollment:
Participant gender:
Summary
This is an open-label, extension trial designed to evaluate safety over 12 additional weeks
of TNX-102 SL therapy taken daily at bedtime for the treatment of PTSD. Patients recruited
into this trial are those who have successfully completed the double-blind lead-in study.